Last updated on May 2017

First-in-man Dose Escalation Study of ALX-009 and Its Components in Healthy Men and Cystic Fibrosis Suffering Patients


Brief description of study

This is a Phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics of a single ascending doses (SAD) and multiple ascending doses (MAD) of Hypothiocyanite (OSCN-), bovine lactoferrin (bLF) and their combination (ALX-009) in healthy male volunteers and patients suffering from cystic fibrosis.

Detailed Study Description

Part I: SAD of OSCN- and bLF in healthy male volunteers (cohorts 1 to 3) - Part II: SAD and MAD of ALX-009 in healthy male volunteers (cohorts 4 and 5) - Part III: MAD of OSCN- and bLF in patients suffering from cystic fibrosis (cohorts 6 to 8) - Part IV: MAD of ALX-009 in patients suffering from cystic fibrosis (cohorts 9 to 11)

Clinical Study Identifier: NCT02598999

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Yves Donazzolo

Eurofins Optimed
Grenoble, France
  Connect »